日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions

体外培养与患者痰液中持续性结核分枝杆菌的差异:对转化预测的意义

Faraj, Alan; Clewe, Oskar; Svensson, Robin J; Mukamolova, Galina V; Barer, Michael R; Simonsson, Ulrika S H

A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis

基于模型的分析揭示了体外和体内表型耐药性的差异:对结核病转化医学的启示

Clewe, Oskar; Faraj, Alan; Hu, Yanmin; Coates, Anthony R M; Simonsson, Ulrika S H

Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin

利用结核病临床前研究预测临床剂量反应:利福平的转化预测

Wicha, Sebastian G; Clewe, Oskar; Svensson, Robin J; Gillespie, Stephen H; Hu, Yanmin; Coates, Anthony R M; Simonsson, Ulrika S H

A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations

基于模型的临床前方法预测抗结核药物组合的临床药效学相互作用

Clewe, Oskar; Wicha, Sebastian G; de Vogel, Corné P; de Steenwinkel, Jurriaan E M; Simonsson, Ulrika S H

A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells--using rifampicin as an example

以利福平为例,构建预测药物从血浆到肺泡上皮衬液和肺泡细胞分布范围和速率的药代动力学肺部模型

Clewe, Oskar; Goutelle, Sylvain; Conte, John E Jr; Simonsson, Ulrika S H

Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy

胆红素——阿扎那韦类抗逆转录病毒疗法中药物暴露的潜在标志物

Rekić, Dinko; Clewe, Oskar; Röshammar, Daniel; Flamholc, Leo; Sönnerborg, Anders; Ormaasen, Vidar; Gisslén, Magnus; Abelö, Angela; Ashton, Michael